SCHEMBL5886889

SCHEMBL5886889

Cc1nc(N2CCN(C(=O)c3ccccc3)CC2)nc2c1ccc(=O)n2-c1ccc(C(=O)NCc2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 4/20 0.45
SLC6A7 Q99884 1/20 0.41
EPHX2 P34913 1/20 0.41
MAPK8 P45983 1/20 0.41
MAPK14 Q16539 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
MGLL Q99685 3/20 0.40
NAMPT P43490 1/20 0.40
ENPP2 Q13822 1/20 0.40
MEN1 O00255 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
SCD O00767 1/20 0.39
BRAF P15056 1/20 0.39
PRKAB2 O43741 1/20 0.39
PRKAG1 P54619 1/20 0.39
PRKAA2 P54646 1/20 0.39
PRKAA1 Q13131 1/20 0.39
PRKAG3 Q9UGI9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887675 0.93 SLC6A7 (0.44) MAPK10SLC6A7MGLLMEN1CYP2C19
SCHEMBL5886918 0.92 CTNNB1 (0.43) EPHX2MAPK8MAPK14NAMPTMEN1
SCHEMBL5886763 0.92 SMN1; SMN2 (0.42) EPHX2MAPK14NAMPTENPP2MEN1
SCHEMBL5887563 0.92 EPHX2 (0.42) MAPK10SLC6A7EPHX2NAMPTENPP2
SCHEMBL5886912 0.91 ME2 (0.43) EPHX2MAPK14NAMPTENPP2MEN1
SCHEMBL5886791 0.91 ENPP2 (0.48) EPHX2ENPP2MEN1CYP2C19KMT2A
SCHEMBL5886700 0.90 MGLL (0.42) MAPK10SLC6A7MAPK8MGLLMEN1
SCHEMBL5887356 0.90 RAB9A (0.43) MEN1KMT2ASMN1; SMN2
SCHEMBL5886869 0.90 HIF1A (0.47) EPHX2SIGMAR1MEN1KMT2APRKAB2
SCHEMBL5887652 0.89 SMN1; SMN2 (0.42) EPHX2MAPK8MAPK14NAMPTENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP MAPK10 1723/4885SLC6A7 4248/4885EPHX2 2968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.